Literature DB >> 3056693

Immunosuppressive drugs and corticosteroids in the treatment of rheumatoid arthritis.

M Arnold1, L Schrieber, P Brooks.   

Abstract

Rheumatoid arthritis is the most common form of severe inflammatory arthropathy affecting patients at a relatively early age. Although there are a number of drugs which significantly reduce pain and swelling, few alter the development of erosions and progression of joint destruction. A significant number of patients with rheumatoid arthritis develop this progressive disability and will require treatment with corticosteroids or immunosuppressive agents. In this article the use of immunosuppressive drugs and corticosteroids in the treatment of aggressive rheumatoid arthritis is reviewed. Controlled clinical trials have shown that a number of these drugs can play a significant role in reducing pain and swelling and might possibly alter the disease course in rheumatoid arthritis. Side effects of these agents, including the potential for oncogenesis, still pose major problems in their long term use. The risks and benefits of immunosuppressive and corticosteroid drug therapy must be balanced in each patient to whom they are prescribed and reviewed at frequent intervals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056693     DOI: 10.2165/00003495-198836030-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  130 in total

Review 1.  Nonassociation of adrenocorticosteroid therapy and peptic ulcer.

Authors:  H O Conn; B L Blitzer
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

2.  Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates.

Authors:  J M Kremer; J Galivan; A Streckfuss; B Kamen
Journal:  Arthritis Rheum       Date:  1986-07

3.  Severe dermatomyositis treated with cyclosporin A.

Authors:  L Ejstrup
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

4.  Immunosuppressive drugs in the management of malignant and severe rheumatoid arthritis.

Authors:  M F Kahn; M Bedoiseau; S de Sèze
Journal:  Proc R Soc Med       Date:  1967-02

5.  Conversion from daily to alternate daily corticosteroids in rheumatoid arthritis.

Authors:  M A Fitzcharles; J Halsey; H L Currey
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

6.  Controlled trial of cyclophosphamide in rheumatoid arthritis.

Authors:  A S Townes; J M Sowa; L E Shulman
Journal:  Arthritis Rheum       Date:  1976 May-Jun

7.  Side effects of cyclosporin A treatment in patients with rheumatoid arthritis.

Authors:  K J Berg; O Førre; F Bjerkhoel; E Amundsen; O Djøseland; H E Rugstad; B Westre
Journal:  Kidney Int       Date:  1986-06       Impact factor: 10.612

8.  Methotrexate therapy in rheumatoid arthritis: 15 years experience.

Authors:  R T Hoffmeister
Journal:  Am J Med       Date:  1983-12-30       Impact factor: 4.965

9.  Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis.

Authors:  T M Hansen; E Dickmeiss; H Jans; T Ingemann Hansen; M Ingeman-Nielsen; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

10.  Survival, prognosis, and causes of death in rheumatoid arthritis.

Authors:  D M Mitchell; P W Spitz; D Y Young; D A Bloch; D J McShane; J F Fries
Journal:  Arthritis Rheum       Date:  1986-06
View more
  4 in total

1.  Acute myelogenous leukemia in a rheumatoid arthritis patient under cyclosporine A therapy.

Authors:  P Casoli; B Tumiati
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 2.  Utilization patterns of non-steroidal anti-inflammatory drugs in an open Dutch population.

Authors:  H G Leufkens; C B Ameling; Y A Hekster; A Bakker
Journal:  Pharm Weekbl Sci       Date:  1990-06-22

Review 3.  Rheumatoid arthritis in the aged. Incidence and optimal management.

Authors:  G Nesher; T L Moore
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

4.  [Pain of the joint of inflammatory diseases pathobiochemistry and pharmacology.].

Authors:  K Resch
Journal:  Schmerz       Date:  1991-03       Impact factor: 1.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.